You are here

Article Text

Article menu

Download PDFPDF

Cardiovascular and metabolic risk
Circulating SerpinB1 levels and clinical features in patients with type 2 diabetes
  1. Kohzo Takebayashi,
  2. Kenji Hara,
  3. Tomoko Terasawa,
  4. Rika Naruse,
  5. Mariko Suetsugu,
  6. Takafumi Tsuchiya,
  7. Toshihiko Inukai
  1. Department of Internal Medicine, Dokkyo Medical University Koshigaya Hospital, Koshigaya, Saitama, Japan
  1. Correspondence to Dr Kohzo Takebayashi; takeb{at}gmail.plala.or.jp

Abstract

Objective The main purpose of this study was to investigate the association of serum SerpinB1 levels and various parameters in patients with type 2 diabetes. The effect of canagliflozin (a sodium glucose cotransporter 2 (SGLT2) inhibitor), which can decrease circulating insulin levels, on serum SerpinB1 levels was also investigated. A recent study suggests that the serum levels of SerpinB1, also known as monocyte neutrophil elastase inhibitor, increase with insulin resistance, may have a protective effect for pancreatic β cells, and may decrease insulin resistance.

Research design and methods The study included 30 patients with type 2 diabetes hospitalized for glycemic control and 10 control subjects.

Results SerpinB1 levels were significantly higher in patients with type 2 diabetes, compared with that in heathy control subjects (10.01±3.59 vs 5.69±1.64 ng/mL, p<0.0001). Serum SerpinB1 levels had a significant negative correlation with low-density lipoprotein cholesterol (LDL-C) (p=0.0123). Serum SerpinB1 levels had a significant positive association or trend toward a positive association with age and with hemoglobin A1c (HbA1c), and significant negative association with LDL-C levels in some multiple regression analysis models. Patients treated with statins had a tendency toward higher serum SerpinB1 levels, compared with those patients not treated with statins. During a 3-day observation period both with and without canagliflozin treatment, the serum SerpinB1 levels did not change.

Conclusions Serum SerpinB1 levels are elevated in patients with type 2 diabetes compared with that in healthy subjects and are negatively correlated with serum LDL-C.

  • Serpin
  • Type 2 Diabetes
  • LDL Cholesterol

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

https://doi.org/10.1136/bmjdrc-2016-000274

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors KT, KH, TT, RN, MS, TT, TI researched data. KT wrote this manuscript. TI reviewed this manuscript.

    • Competing interests None declared.

    • Patient consent Obtained.

    • Ethics approval Local Ethics Committee at Dokkyo Medical University Koshigaya Hospital.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data sharing statement No additional data are available.